PDCD1 and hepatocellular carcinoma: Immune checkpoint inhibitors, such as nivolumab and pembrolizumab, which target programmed cell death protein-1 (PD1) mainly enhance the T-cell response to tumors, thus improving the prognoses of patients with HCC (3, 4).